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BACKGROUND: When standard doses of inhaled corticosteroids (ICS) fail to control symptoms in children aged 44 years,
guidelines recommend the addition of a long-acting β2-agonist (LABA), with other treatment options being available if symptoms
persist.
AIMS: To determine the proportion of initial ‘step-up’ episodes where LABAs were prescribed and to describe characteristics of
individuals not stepped up with LABA.
METHODS: Between 1999 and 2011, initial step-up episodes from ICS monotherapy were identiﬁed in children aged 5–12 years
with asthma and in receipt of ICS. Data sources were the Clinical Practice Research Datalink and Optimum Patient Care Research
Database.
RESULTS: Initial step-up episodes were identiﬁed in 10,793 children. ICS dose was increased in 6,252 children (58%), LABA was
introduced in 3,436 (32%; including 1,107 where ﬁxed dose combination inhaler (FDC) replaced the ICS inhaler), and leukotriene
receptor antagonist (LTRA) was added in 1,105 (10%). Compared with children stepped up to any LABA, others were younger and
prescribed lower doses of ICS and reliever medication. ICS dose increase was more likely in obese children and LTRA prescribing
was more likely in children with rhinitis and in receipt of antibiotics. Compared with FDC, step-up to separate LABA inhaler was
more likely in younger, obese children who were using less oral steroids.
CONCLUSIONS: One-third of initial step-up episodes in children with asthma treated with ICS are to add LABA. Different
characteristics of children prescribed therapies other than LABA suggest that prescribers tailor treatment in some clinical settings.
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INTRODUCTION
Asthma is a common condition1 and 5% of children in the UK are
prescribed inhaled corticosteroids (ICS) to control asthma
symptoms.2 Annually there are over 25,000 children admitted to
hospital for asthma in England and Wales3 and the cost of asthma
inhaler prescriptions issued in the UK to children aged 5–15 years
is ~ £37million,4 which is equivalent to £5 for every child in the
population. Treatment with low dose ICS is effective in controlling
symptoms for the majority of children but ~ 10% of children
require one of four additional ‘step-up’ treatment options.1,2
Clinical trials have demonstrated that many children will beneﬁt
from more than one step-up option5–10 but equally, some will gain
greatest beneﬁt from one of the options.5,10
In the absence of evidence for a ‘best’ step-up option,
guidelines for asthma management in children advocate either
addition of LABA1,11 or increasing ICS dose12 as the ﬁrst step-up
option while highlighting the need to assess response and
prescribe an alternative treatment for non-responders. More
recent guidance recommends that step-up to ﬁxed dose
combination inhaler (FDC) containing ICS and LABA is preferable
to addition of separate LABA inhaler due to better adherence to a
single inhaler device.13 What is not known is whether these
guidelines1,13 have been put into practice and our main research
question was ‘in what proportion of ﬁrst step-up episodes is LABA
treatment added to ICS rather than ICS dose increased or LTRA
added?’. Given the uncertainty as to which initial treatment step-
up is most effective, we anticipated that some children would be
stepped up to treatment other than LABA and tested the null
hypothesis that children stepped up to LTRA or increased ICS
would be no different to those stepped up to LABA; the presence
of differences between those stepped up to LABA and to other
medications would suggest that prescribers recognise subgroups
who they feel are more likely to respond to options other than
LABA. We tested our research question and hypothesis using
routinely acquired ‘real life’ data from primary care, an approach
which complements results from clinical trials14 and has been
used in the paediatric setting15 and also, in adults, in the context
of stepping up treatment.16
MATERIALS AND METHODS
Study population
Prescribing data were obtained from the CPRD and the OPCRD between 1
January 1990 and 23 December 2011 for OPCRD and 11 April 2011 for
CPRD. Data before 1 January 1999 were not included since LTRA and
FDC inhalers were not licensed for use in the UK until 1998 and 1999,
respectively. Inclusion criteria were (i) asthma diagnosis, deﬁned as
a Read code for asthma and/or 41 prescription for asthma medications
(including ⩾ 1 for ICS) in the 12 months prior to the ﬁrst step-up
date (index date), (ii) aged 5–12 years when treatment stepped up
to allow comparison with recommendations for this age range set out in
the BTS/SIGN guideline,1 (iii) registered with the practice for at least
12 months prior to and post index date. Exclusion criteria were (i) other
chronic respiratory disease, (ii) maintenance oral steroid prescribed in
the 12 months prior to the index date, (iii) previous prescription for LABA
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(as separate or FDC inhaler), LTRA or theophylline in the year prior
to the index date, (iv) multiple step-up therapies, multiple ICS, or
prescription of both FDC and ICS inhalers at index date, (v) ICS step-up
dose by o50%,17 and (vii) prescribed theophylline at step-up (due to small
numbers).
Study design
Patients were categorized according to their ﬁrst step-up as: (i) addition of
LABA, ICS dose unchanged, (ii) increase ICS dose, (iii) addition of LTRA, ICS
dose unchanged, and (iv) replacement of ICS inhaler with FDC. Distinction
was made between FDC and addition of separate LABA inhaler since the
former is the recommended option.13 This study was approved in 2010 by
the Independent Scientiﬁc Advisory Committee of the (then) General
Practice Research Database.
Predictor variables (or patient characteristics)
Patient characteristics and asthma medication use were deﬁned over the
12 months prior to step-up. Rhinitis diagnosis was ‘rhinitis ever’ as coded in
primary care (Read) records. Eczema medications were those prescribed in
the 12 months prior to step-up. SABA use was deﬁned as any prescription
in the baseline year. Body mass index (BMI) was derived from height and
weight and converted to centiles and z-scores with reference to the 1990
UK standard18 applying clinical cutoffs for overweight (⩾91st centile) and
obese (⩾98th centile). BMI z-scores outside the range ± 5 were excluded as
presumed data entry mistake.19 Paracetamol prescription in the previous
year was included since this is a confounder in adult studies.20 Ethnicity
data were not available. The online supplement describes the methods for
deriving the following variables: average daily ICS dosage, average daily
short-acting β2-agonist (SABA) use, acute oral steroid use, and medication
possession ratio.
Clinical practice research datalink
The Clinical practice research datalink (CPRD), initially the General Practice
Research Database, was established in 1990 and by 1999 included a stable
population of 650 practices across the UK and provided primary care
prescribing for ~ 5% of the population. (http://www.cprd.com/intro.asp).
Optimum patient care research database
The Optimum Patient Care Research Database (OPCRD) was established in
2008 and currently has 424 practices in the database. Patients with
respiratory conditions are actively recruited. The OPCRD holds data from
1,200,014 patients including 514,719 with asthma; therefore OPCRD has
data on ~ 10% of the UK asthma population. Algorithms identify any
patients included from both CPRD and OPCRD and remove duplicates.
(http://www.optimumpatientcare.org/Html_Docs/OPCRD.html).
Statistical analysis
Differences across the categories of ICS dose increases and also the
univariate associations between ﬁrst post ICS step-up therapy and
each patient characteristic or baseline asthma medication variable were
tested using a Χ2-test for categorical variables and Kruskal–Wallis for
variables measured on the interval or ratio scale. A multivariate regression
model was built using multinomial logistic regression with FDC as the
reference group, by ﬁrst including age, sex, index year, and all variables
with univariate associations with Po0.1 in the model. Variables were
examined for co-linearity and clinical importance then removed in a
backwards stepwise procedure until all variables remaining in the
multivariate model had Po0.1. Since addition of LABA has until recently
been the recommended ﬁrst step-up option, we repeated analyses with
this option as the reference. All analyses were carried out using SAS
version 9.3 (SAS, Cary, NC, USA).
RESULTS
Study subjects
Data were available in 10,793 individuals (7,609 from OPCRD)
whose median (interquartile range) age was 9 (6–11) years, 59%
were male, 97% had a diagnosis of asthma, and 50% were
prescribed eczema medications (Table 1). Figure 1 shows how
individuals were identiﬁed from the databases. There were 6,252
children where ICS dose was increased (58%), 2,329 were
prescribed a separate LABA inhaler (22%), 1,107 switched to FDC
(10%), and 1,105 had LTRA added (10%). Table 2 describes the
characteristics of individuals where ICS dose was increased
stratiﬁed by dose increase option. These seven groups included
96% of all ICS dose step-up episodes and differed by age and year
when step-up was made. The most common ICS dose increase
was from 200 to 400 µg (budesonide equivalent) which was
prescribed in 4,135 children (66% of the ICS dose increase group).
Table 1. Characteristics of the 10,793 children with asthma in receipt
of inhaled steroid treatment where a ﬁrst step-up was made
n (%)
Median age (Interquartile range), years 9 (6, 11)
Female gender 4,457 (41.3%)
BMI centile
o91th 4,241 (39.3%)
91–97th 825 (7.6%)
⩾ 98th 869 (8.1%)
Missing 4,858 (45.0%)
Rhinitis diagnosis 2,497 (23.1%)
Eczema drugs 5,360 (49.7%)
Asthma diagnosis 10,447 (96.8%)
Median year of index date (Interquartile range) 2004 (2002, 2007)
Time of ﬁrst asthma prescription
Years before IPD:
0–1 3,460 (32.1%)
2–3 3,056 (28.3%)
4–5 2,314 (21.4%)
6+ 1,963 (18.2%)
Average ICS daily dosage (µg)a
40–100 5,028 (46.6)
101–200 3,392 (31.4)
201+ 2,373 (22.0)
Medication possession ratio ⩾ 80%a 2,479 (23.0%)
Any SABA prescriptiona 10,294 (95.4%)
Mean daily SABA dosage (µg)a
0 499 (4.6%)
40–200 5,874 (54.4%)
201+ 4,420 (41.0%)
Acute oral steroid prescriptiona 1,034 (9.6%)
Asthma-related out-patient visita 99 (0.9%)
Asthma-related in-patient visita 51 (0.5%)
Asthma-related A&E visita 56 (0.5%)
Antibiotics with evidence of respiratory reviewa
0 7,656 (70.9%)
1 2,107 (19.5%)
2+ 1,030 (9.5%)
GP consultations for asthmaa
0 2,655 (24.6%)
1 3,113 (28.8%)
2 2,419 (22.4%)
3+ 2,606 (24.2%)
GP consultations not for asthmaa
0 1,117 (10.4%)
1–2 3,033 (28.1%)
3–5 3,553 (32.9%)
6+ 3,090 (28.6%)
The table displays number of children (n) unless speciﬁed otherwise.
Abbreviations: A&E= accident and emergency; GP=general practitioner;
ICS, inhaled corticosteroids; IPD= index prescribing date; SABA,
short-acting β2-agonist;.
aThese variables are with respect to the 12 months prior to step-up.
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Supplementary Table E1 presents the number of children in each
of the possible 154 ICS step-up dose categories.
Changes over time and univariate differences between groups
The incidence of ICS step-up fell between 1999 and 2005,
coinciding with a rise in overall LABA prescribing (that is, FDC
plus separate LABA inhaler), but remained static between 2005
and 2011 (Figure 2). The incidence of all LABA prescribing fell and
LTRA prescribing rose between 2005 and 2011 (Figure 2 and
online Supplementary Table E2). In univariate analyses, the
following characteristics at baseline differed across the four
treatment groups: age, year when step-up was made, obesity,
eczema, daily dose of ICS, medication possession ratio, need for
SABA use, oral corticosteroid, and antibiotics in the previous year,
primary care consultations, and data source (OPCRD versus CPRD)
(Table 3).
Multivariate analysis
In the multivariate analysis and in comparison with all other
groups, children in the FDC group were older and more likely to
have seen the GP for asthma (Table 4). The FDC group was more
likely to have received oral steroid treatment but less likely to have
received antibiotics compared with the LABA and LTRA groups,
less likely to be obese and more likely to have regular use of SABA
Figure 1. CONSORT diagram showing how the individuals included in the present study were identiﬁed within the CPRD and OPCRD
databases. *IPD= index prescription date.
Table 2. Characteristics of children where ICS dose was stepped up by different increments
Dose prior to
step-up to dose
after step-up, µg
BDP equivalent (n)
Mean (s.d.)
index year
Male,
n (%)
Mean
(s.d.)
age, years
Rhinitis
diagnosis,
n (%)
Eczema
drugs, n (%)
SABA
prescription,
n (%)
Median (IQR) daily
SABA dosage, µg
Acute oral
steroid
prescription, n (%)
Antibiotics
prescriptiona,
n (%)
100–200 (732) 2004.7 (3.4) 421 (57.5) 8.0 (2.1) 143 (19.5) 386 (52.7) 684 (93.4) 147.9 (54.8, 219.2) 64 (8.7) 206 (28.1)
100–400 (265) 2003.8 (3.1) 158 (59.6) 8.3 (2.3) 53 (20.0) 138 (52.1) 250 (94.3) 164.4 (109.6, 274.0) 21 (7.9) 82 (30.9)
200–400 (4,135) 2004.4 (3.3) 2,418 (58.5) 8.5 (2.3) 959 (23.2) 2,091 (50.6) 3,896 (94.2) 164.4 (54.8, 274.0) 337 (8.1) 1,148 (27.8)
200–800 (204) 2003.0 (3.3) 120 (58.8) 8.4 (2.2) 45 (22.1) 94 (46.1) 184 (90.2) 109.6 (54.8, 274.0) 15 (7.4) 45 (22.1)
200–1,000 (80) 2003.1 (3.3) 40 (50.0) 7.4 (2.2) 16 (20.0) 42 (52.5) 77 (96.3) 219.2 (109.6, 328.8) 5 (6.3) 16 (20.0)
400–800 (364) 2003.5 (3.3) 215 (59.1) 9.2 (2.3) 75 (20.6) 163 (44.8) 346 (95.1) 147.9 (104.1, 274.0) 30 (8.2) 104 (28.6)
400–1000 (194) 2002.5 (2.7) 120 (61.9) 8.5 (2.5) 47 (24.2) 83 (50.2) 184 (94.8) 164.4 (54.8, 274.0) 18 (9.3) 49 (25.3)
P valueb o0.001 0.71 o0.001 0.31 0.05 0.26 0.27 0.98 0.25
The seven increments described account for 96% of all ICS step-ups.
Abbreviations: BDP, budesonide diproprionate; ICS, inhaled corticosteroids; IQR, interquartile range; SABA, short-acting β2-agonist.
aAntibiotics prescribed with evidence of respiratory review.
bΧ2-test for categorical variables and Kruskal–Wallis for variables measured on the interval or ratio scale.
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compared with the ICS dose increase group, and more likely to
have received an average daily dose of ICS 4200 µg (BDP
equivalent) than ICS and LTRA groups (Table 4). Children in the
LTRA group were more likely to have rhinitis and to have received
more than one antibiotic for respiratory symptoms in the previous
year (Table 4). Supplementary Table E3 compares the character-
istics of children in treatment groups with reference to addition of
a separate LABA inhaler.
DISCUSSION
Main ﬁndings
This is the ﬁrst study to describe which initial ‘step-up’
asthma treatment options are made for 5–12-year-old children
in the UK, and also the ﬁrst to describe the characteristics of
children who receive different step-up options. The ﬁrst main
ﬁnding was that step-up with increasing ICS dose remained the
most popular step-up option between 1999 and 2011 despite
national guidelines recommending step-up with LABA before
considering increasing ICS dose to 400 µg BUD equivalent per
day.1 The second novel ﬁnding was that children who were
stepped up to medication other than LABA had a number of
characteristics which were subtly different to those where LABA
was introduced (Figure 3), and this suggests that clinicians may be
making active decisions not to add LABA. Our results are based on
observations from ~15% of children in England and are therefore
likely to be generalisable. The hypothesis that children with some
characteristics, for example, obesity and rhinitis, gain greater
beneﬁt from treatment other than LABA needs to be tested in
large populations.
Strengths and limitations of this study
There are a number of strengths and limitations to this study.
Strengths include the large number of individuals included,
adjustment for health seeking behaviour, and collection of
prescriptions and the use of routine data, which avoids the
bias in recruitment which can occur in clinical trials making
generalisation unreliable.14 A limitation of routinely entered data
is that data are incomplete leading to some individuals being
excluded. A second limitation to our study is that data were not
complete for all individuals studied, for example, BMI was
available for 65% of children, and while missing values might
not be at random we have demonstrated that children with
missing BMI data were equally distributed across step-up groups.
A ﬁnal limitation is that in an observational study such as ours,
causation cannot necessarily be inferred from the associations
described.
Interpretation of ﬁndings in relation to previously published work
The majority of initial step-up episodes were to increase ICS dose,
and over 70% of these were increases to a daily dose of 400 µg
budesonide equivalent. Approximately 10% of ICS step-ups were
from a daily dose of 100 to 200 µg budesonide, and although
these occurred in a younger group of individuals, suggesting that
clinicians were being more cautious with ICS dose in younger
children, it is possible that some incidents represented ‘ﬁne
tuning’ doses from an initially very low value to the dose
suggested for step 2 treatment.1 Notwithstanding this small
number of step-ups to 200 µg, the majority of ICS step-ups were
consistent with a move to the BTS/SIGN step 3 treatment step but
these episodes were not preceded with LABA treatment and this is
not consistent with the guideline.1
Table 2 demonstrates that the majority (69%) of ICS step-up
options were from 200 to 400 µg budesonide per day, and this
suggests that that clinicians looking after patients in the real world
have found that stepping up from low to intermediate ICS dose is
a safe and effective option and that this accounts for its relative
popularity. Eight percent of ICS step-ups were either from low
direct to high dose or to ICS dose in excess of the ceiling dose of
800 µg budesonide equivalent and these observations replicate
our earlier work highlighting the prevalence of high dose ICS
prescribing.2 The BTS/SIGN1 guideline suggests that children in
receipt of high dose ICS (that is, 800 µg budesonide per day)
should receive speciﬁc written advice about steroid replacement
and be under the care of a specialist paediatrician.
Asthma prescribing is known to deviate from guidelines in the
UK,21,22 and other countries,23,24 and might in part be due to a
delay between guidelines being published and implemented;
other reasons for prescribing changes include falls in pricing as
medications come off patent and concerns about adverse effects
of LABA therapy raised by the United States Food and Drug
Administration in 2005.25 The BTS/SIGN guidelines ﬁrst recom-
mend LABA addition rather than increasing ICS dose since 1995,26
and this change in advice might explain the continuing rise in
LABA prescribing between 1999 and 2005. The 2003 BTS/SIGN
guideline was the ﬁrst to recommend inclusion of LTRA27 but this
advice was anticipated since 100,000 LTRA prescriptions for
children were made in 200322 and we see rising LTRA prescribing
in the early 2000s. What is notable is that despite LABA being
advocated as the ﬁrst step by guidelines since 1995, the rise in
LABA prescribing pre 2006 has faltered, as has been demonstrated
previously2,22 and here we show a decline in LABA prescribing
between 2006 and 2011; this study cannot explain why LABAs are
less frequently prescribed but one explanation might be that
prescribers ﬁnd LTRA or increasing ICS dose to be more effective.
An alternative explanation for increasing step-up by addition of
LTRA or increasing ICS in younger children within the 5–12-year-
old category may be ‘carry over’ of more recent BTS/SIGN1 and
GINA12 guideline advice to use these step-up options in the
o5-year-old category.
Implications for future research, policy and practice
The presence of differences between individuals in the step-up
option groups suggests that prescribers perceive that some
individuals gain beneﬁt from speciﬁc step-up options. In a tertiary
Figure 2. Proportion of step-up options over time in children with
asthma already in receipt of inhaled corticosteroid treatment (ICS).
All LABA, FDC plus LABA; FDC, ﬁxed dose combination inhaler;
LABA, addition of long-acting β2-agonist as separate inhaler; LTRA,
leukotriene receptor antagonist. Data from 2010 and 2011 are
combined since data from the whole of the calendar year 2011 were
not available from CPRD. The vertical broken lines indicate when
British Thoracic Society/Scottish Intercollegiate Guidelines network
(BTS/SIGN) asthma guidelines were published.
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Table 3. Patient characteristics according to ﬁrst step-up therapy during 1999–2011
FDC (n=1,107) Add LABA
(n=2,329)
Increase ICS dose
(n=6,252)
Add LTRA
(n= 1,105)
P valuea
Median (IQR) age, years 10 (8, 11) 9 (6, 11) 8 (6, 10) 8 (6, 10) o0.001
Male sex 660 (59.6) 1,343 (57.7) 3,663 (58.6) 670 (60.6) 0.37
Median (IQR) BMI centile
Median (IQR) 65 (29, 93) 68 (28, 94) 67 (31, 93) 65 (31, 93) 0.13
Missing, n (%) 457 (41.3) 1,076 (46.2) 2,875 (46.0) 450 (40.7)
BMI centile, categorised
o91th 467 (42.2) 881 (37.8) 2427 (38.8) 466 (42.2) o0.001
91–97th 102 (9.2) 175 (7.5) 440 (7.0) 108 (9.8)
⩾ 98th 81 (7.3) 197 (8.5) 510 (8.2) 81 (7.3)
Missing 457 (41.3) 1,076 (46.2) 2,875 (46.0) 450 (40.7)
Rhinitis diagnosis 243 (22.0) 575 (24.7) 1,404 (22.5) 275 (24.9) 0.06
Eczema drugs 552 (49.9) 1,085 (46.6) 3,149 (50.4) 574 (51.9) 0.006
Paracetamol prescription 162 (14.6) 316 (13.6) 915 (14.6) 175 (15.8) 0.34
Asthma diagnosis 1,073 (96.9) 2,247 (96.5) 6,067 (97.0) 1,060 (95.9) 0.19
Median (IQR) index year 2006 (2004, 2008) 2004 (2002, 2006) 2004 (2001, 2007) 2007 (2004, 2008) o0.001
First asthma prescription 41 year before index date 771 (69.7) 1,552 (66.6) 4,258 (68.1) 752 (68.1) 0.34
Average ICS daily dosage (µg)
40–100 379 (34.2) 792 (34.0) 3,400 (54.4) 457 (41.4) o0.001
101–200 387 (35.0) 818 (35.1) 1,811 (29.0) 376 (34.0)
201+ 341 (30.8) 719 (30.9) 1,041 (16.7) 272 (24.6)
Medication possession ratio
⩾ 80% 211 (19.1) 506 (21.7) 1,516 (24.2) 246 (22.3) o0.001
SABA prescription
1+ 1,083 (97.8) 2,261 (97.1) 5,883 (94.1) 1,067 (96.6) o0.001
Mean daily SABA dosage (µg)
0 24 (2.2) 68 (2.9) 369 (5.9) 38 (3.4) o0.001
40–200 584 (52.8) 1,229 (52.8) 3,478 (55.6) 583 (52.8)
201+ 499 (45.1) 1,032 (44.3) 2,405 (38.5) 484 (43.8)
Acute oral steroid use
⩾ 1 156 (14.1) 237 (10.2) 512 (8.2) 129 (11.7) o0.001
Asthma-related out-patient visit
⩾ 1 14 (1.3) 18 (0.8) 48 (0.8) 19 (1.7) 0.01
Asthma-related In-patient visit
⩾ 1 11 (1.0) 9 (0.4) 22 (0.4) 9 (0.8) 0.01
Asthma-related A&E visit
⩾ 1 6 (0.5) 6 (0.3) 36 (0.6) 8 (0.7)
Antibiotics with evidence of respiratory review
0 800 (72.3) 1,631 (70.0) 4,523 (72.3) 702 (63.5) o0.001
1 210 (19.0) 470 (20.2) 1,199 (19.2) 228 (20.6)
2+ 97 (8.8) 228 (9.8) 530 (8.5) 175 (15.8)
GP consultations for asthma
0 180 (16.3) 524 (22.5) 1,663 (26.6) 288 (24.6) o0.001
1 297 (26.8) 580 (24.9) 1,950 (31.2) 286 (25.9)
2 249 (22.5) 530 (22.8) 1,405 (22.5) 235 (21.3)
3+ 381 (34.4) 695 (29.8) 1,234 (19.7) 296 (26.8)
GP consultations not for asthma
0 99 (8.9) 240 (10.3) 713 (11.4) 65 (5.9) o0.001
1–2 314 (28.4) 618 (26.5) 1,847 (29.5) 254 (23.0)
3–5 359 (32.4) 800 (34.3) 2,033 (32.5) 361 (32.7)
6+ 335 (30.3) 671 (28.8) 1,659 (26.5) 425 (38.5)
OPCRD data source (versus CPRD) 740 (66.8) 1,709 (73.4) 4,378 (70.0) 782 (70.8) o0.001
Numbers denote n (%) unless speciﬁed otherwise.
Abbreviations: BMI, body mass index; CPRD, Clinical Practice Research Datalink; FDC, ﬁxed dose combination inhaler; ICS, inhaled corticosteroids; IQR,
interquartile range; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; OPCRD, Optimum Patient Care Research Database.
aΧ2-test for categorical variables and Kruskal–Wallis for variables measured on the interval or ratio scale.
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care setting, clinicians have previously been shown to prescribe
asthma medications by phenotype, that is, viral wheeze versus
multitrigger wheeze,28 with the implication that some individuals
are recognised as having preferential response to some asthma
medications. In one study, differential response to step-up therapy
has been linked to age, the presence of eczema and ethnicity,5
while in a second study increased reliever medication use,
increased exhaled nitric oxide, and reduced lung function were
more likely following increasing ICS dose compared with the
addition of LTRA.10 Obese children are less responsive to ICS
therapy,29 but obese children were 40% more likely to have ICS
step-up rather than addition of FDC in our study. We observed
that children stepped up to LTRA had a higher prevalence of
rhinitis and a 70% increased risk for multiple prescriptions for
antibiotics for respiratory symptoms, when compared with both
LABA step-up options, and this decision may be justiﬁable since
LTRA are known to be effective against upper and lower
respiratory tract symptoms.30 Our study raises at least two
research questions which we will address in future work: (i) what
are the outcomes of stepping up asthma treatment using FDC as
the gold standard in comparison with increasing ICS or addition of
LTRA or LABA separately?; (ii) are there patient subgroups (or
phenotypes) who gain preferential response from options other
than step-up to FDC?
Table 4. Multivariate associations between patient characteristics and step-up treatment in children with asthma whose treatment was stepped up
from ICS treatment with reference to change to ﬁxed dose combination inhaler
Add LABA (n=2,329) Increase ICS dose
(n=6,252)
Add LTRA (n= 1,105) P value
OR 95% CI OR 95% CI OR 95% CI
Age per year 0.87 0.84, 0.90 0.86 0.83, 0.88 0.79 0.76, 0.82 o0.001
BMI centile
o91th 1.00 1.00 1.00 0.05
91–97th 1.02 0.78, 1.35 0.96 0.75, 1.23 1.24 0.91, 1.68
⩾ 98th 1.45 1.08, 1.93 1.41 1.08, 1.83 1.14 0.81, 1.60
missing 1.06 0.90, 1.25 0.98 0.85, 1.14 1.00 0.83, 1.21
Index year per
year
0.83 0.81, 0.85 0.85 0.83, 0.87 1.05 1.02, 1.08 o0.001
Rhinitis diagnosis 1.10 0.92, 1.31 1.02 0.86, 1.19 1.30 1.06, 1.59 0.01
Eczema drugs 0.89 0.77, 1.04 1.12 0.98, 1.28 1.00 0.84, 1.18 o0.001
Average ICS daily dosage (µg)
40–100 1.00 1.00 1.00 o0.001
101–200 1.00 0.83, 1.20 0.50 0.43, 0.59 0.83 0.68, 1.03
201+ 0.90 0.73, 1.10 0.29 0.24, 0.35 0.69 0.54, 0.87
SABA daily dosage (µg)
0 1.00 1.00 1.00 o0.001
40–200 0.90 0.56, 1.47 0.40 0.26, 0.62 0.63 0.37, 1.07
201+ 0.98 0.60, 1.59 0.55 0.36, 0.86 0.73 0.42, 1.24
Acute oral steroid use
1+ 0.71 0.56, 0.90 0.68 0.55, 0.84 0.89 0.68, 1.17 0.001
Asthma-related out-patient visit
1+ 0.59 0.29, 1.22 0.58 0.31, 1.08 1.14 0.56, 2.33 0.06
Antibiotics with evidence of respiratory review
0 1.00 1.00 1.00 0.008
1 1.21 1.00, 1.47 1.15 0.96, 1.37 1.14 0.91, 1.43
2+ 1.27 0.96, 1.67 1.21 0.94, 1.56 1.68 1.25, 2.25
GP consultations for asthma
0 1.00 1.00 1.00 o0.001
1 0.86 0.69, 1.08 0.87 0.71, 1.06 0.61 0.47, 0.78
2 0.97 0.76, 1.22 0.78 0.63, 0.97 0.59 0.45, 0.77
3+ 0.74 0.59, 0.93 0.45 0.37, 0.55 0.46 0.36, 0.60
GP consultations not for asthma
0 1.00 1.00 1.00 0.01
1–2 0.91 0.69, 1.21 0.89 0.69, 1.14 1.20 0.84, 1.72
3–5 1.12 0.85, 1.47 0.91 0.71, 1.17 1.32 0.93, 1.88
6+ 1.04 0.78, 1.38 0.84 0.64, 1.08 1.35 0.94, 1.94
Abbreviations: BMI, body mass index; CI, conﬁdence interval; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist;
OR, odds ratio; SABA, short-acting β2-agonist.
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Conclusions
Guidelines are one of the critical components of good clinical
practice but are limited by their one-size-ﬁts-all approach and, in
the case of stepping up asthma treatment in children, often lack
an evidence base. The clinical setting of a child whose asthma
symptoms are not adequately controlled with ICS is common and
there is a lack of evidence for ‘best practice’; in this context it is
appropriate for clinicians to consider guideline advice but not
necessarily apply this advice. Our results demonstrate that
clinicians in the UK frequently do not adhere to the BTS/SIGN
guideline for asthma,1 and deviation from recommendations
appears to be an active decision in circumstances where a number
of coexisting factors are present. An individualised approach may
be more effective in guiding the treatment of asthma beyond step
2 (ICS therapy), which is based around an asthma action plan and
in future guided by genetic factors31 or biomarkers such as
exhaled nitric oxide.32
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